<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34012422</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1664-2392</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in endocrinology</Title>
          <ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oncocytic Change in Thyroid Pathology.</ArticleTitle>
        <Pagination>
          <StartPage>678119</StartPage>
          <MedlinePgn>678119</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">678119</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2021.678119</ELocationID>
        <Abstract>
          <AbstractText>Oncocytes are cells that have abundant eosinophilic cytoplasm due to the accumulation of mitochondria; they are also known as oxyphils. In the thyroid they have been called Hürthle cells but this is a misnomer, since Hürthle described C cells; for this reason, we propose the use of "oncocyte" as a scientific term rather than an incorrect eponym. Oncocytic change occurs in nontumorous thyroid disorders, in benign and malignant tumors of thyroid follicular cells, in tumors composed of thyroid C cells, and intrathyroidal parathyroid proliferations as well as in metastatic lesions. The morphology of primary oncocytic thyroid tumors is similar to that of their non-oncocytic counterparts but also is complicated by the cytologic features of these cells that include both abundant eosinophilic cytoplasm and large cherry red nucleoli. The molecular alterations in oncocytic thyroid tumors echo those of their non-oncocytic counterparts but in addition feature mitochondrial DNA mutations as well as chromosomal gains and losses. In this review we emphasize the importance of recognition of the spectrum of oncocytic thyroid pathology. The cell of origin, morphologic features including architecture, nuclear atypia and invasive growth, as well as high grade features such as mitoses and necrosis, enable accurate classification of these lesions. The molecular alterations underlying the pathological entity are associated with genetic alterations associated with oncocytic change. The arbitrary cut-off of 75% oncocytic change to classify a lesion as an oncocytic variant brings another complexity to the classification scheme of tumors that frequently have mixed oncocytic and non-oncocytic components. This controversial and often confusing area of thyroid pathology requires thoughtful and cautious investigation to clarify accurate diagnosis, prognosis and prediction for patients with oncocytic thyroid lesions.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Asa and Mete.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Asa</LastName>
            <ForeName>Sylvia L</ForeName>
            <Initials>SL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Case Western Reserve University, Cleveland, OH, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University Health Network, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mete</LastName>
            <ForeName>Ozgur</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University Health Network, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Endocrinol (Lausanne)</MedlineTA>
        <NlmUniqueID>101555782</NlmUniqueID>
        <ISSNLinking>1664-2392</ISSNLinking>
      </MedlineJournalInfo>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C536913">Thyroid cancer, Hurthle cell</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018249" MajorTopicYN="N">Adenoma, Oxyphilic</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024862" MajorTopicYN="N">Oxyphil Cells</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013961" MajorTopicYN="N">Thyroid Gland</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013964" MajorTopicYN="N">Thyroid Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Hürthle cell</Keyword>
        <Keyword MajorTopicYN="Y">immunohistochemistry</Keyword>
        <Keyword MajorTopicYN="Y">molecular</Keyword>
        <Keyword MajorTopicYN="Y">neoplasia</Keyword>
        <Keyword MajorTopicYN="Y">oncocytes</Keyword>
        <Keyword MajorTopicYN="Y">thyroid</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34012422</ArticleId>
        <ArticleId IdType="pmc">PMC8127945</ArticleId>
        <ArticleId IdType="doi">10.3389/fendo.2021.678119</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Asa SL. Survival Guide to Endocrine Pathology. Virginia: Innovative Pathology Press;  (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>
Asa SL, Mete O. Parathyroids. In: Mills SE, editor. Histology for Pathologists. Philadelphia: Wolters Kluwer;  (2018). p. 1201–24.</Citation>
        </Reference>
        <Reference>
          <Citation>
Kovacs K, Horvath E, Bilbao JM. Oncocytes in the Anterior Lobe of the Human Pituitary Gland. A Light and Electron Microscopic Study. Acta Neuropathol (Berl) (1974) 27:43–54. 10.1007/BF00687239
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00687239</ArticleId>
            <ArticleId IdType="pubmed">4363741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asa SL, Kovacs K, Bilbao JM. The Pars Tuberalis of the Human Pituitary. A Histologic, Immunohistochemical, Ultrastructural and Immunoelectron Microscopic Analysis. Virchows Arch [A] (1983) 399:49–59. 10.1007/BF00666218
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00666218</ArticleId>
            <ArticleId IdType="pubmed">6299000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nesland JM, Sobrinho-Simoes M, Holm R, Sambade MC, Johannessen JV. Hürthle Cell Lesions of the Thyroid: A Combined Study Using Transmission Electron Microscopy, Scanning Electron Microscopy and Immunocytochemistry. Ultrastructrual Pathol (1985) 8:131–42. 10.3109/01913128509141518
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/01913128509141518</ArticleId>
            <ArticleId IdType="pubmed">4082297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sobrinho-Simoes M, Nesland JM, Holm R, Sambade MC, Johannessen JV. Hürthle Cell and Mitochondrion-Rich Papillary Carcinomas of the Thyroid Gland: An Ultrastructural and Immunocytochemical Study. Ultrastruct Pathol (1985) 8:131–42. 10.3109/01913128509142147
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/01913128509142147</ArticleId>
            <ArticleId IdType="pubmed">4060255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cameselle-Teijeiro J, Ferreira R, Carames N, Abdulkader I, Máximo V, Soares P, et al. . Absence of the BRAF and the GRIM-19 Mutations in Oncocytic (Hurthle Cell) Solid Cell Nests of the Thyroid. Am J Clin Pathol (2012) 137(4):612–8. 10.1309/AJCPB0RXYPACLL5K
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1309/AJCPB0RXYPACLL5K</ArticleId>
            <ArticleId IdType="pubmed">22431538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hurthle K. Beitrage Zur Kenntiss Der Secretionsvorgangs in Der Schilddruse. Arch Gesamte Physiol (1894) 56:1–44. 10.1007/BF01662011
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01662011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Askanazy M. Patologisch Anatomische Beitrage Zur Kenntiss Des Morbus Basedowii, Insbesondere Uber Die Dabei Auftretende Muskelerkrankung. Deutsch Arch Klin Med (1898) 61:118–86.</Citation>
        </Reference>
        <Reference>
          <Citation>
Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M. Mitochondrial DNA Somatic Mutations (Point Mutations and Large Deletions) and Mitochondrial DNA Variants in Human Thyroid Pathology: A Study With Emphasis on Hurthle Cell Tumors. Am J Pathol (2002) 160(5):1857–65. 10.1016/S0002-9440(10)61132-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)61132-7</ArticleId>
            <ArticleId IdType="pmc">PMC1850872</ArticleId>
            <ArticleId IdType="pubmed">12000737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, et al. . Somatic and Germline Mutation in GRIM-19, a Dual Function Gene Involved in Mitochondrial Metabolism and Cell Death, is Linked to Mitochondrion-Rich (Hurthle Cell) Tumours of the Thyroid. Br J Cancer (2005) 92(10):1892–8. 10.1038/sj.bjc.6602547
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6602547</ArticleId>
            <ArticleId IdType="pmc">PMC2361763</ArticleId>
            <ArticleId IdType="pubmed">15841082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mete O, Asa SL. Oncocytes, Oxyphils, Hurthle, and Askanazy Cells: Morphological and Molecular Features of Oncocytic Thyroid Nodules. Endocr Pathol (2010) 21(1):16–24. 10.1007/s12022-009-9102-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-009-9102-2</ArticleId>
            <ArticleId IdType="pubmed">20013317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kimura HJ, Chen CY, Tzou SC, Rocchi R, Landek-Salgado MA, Suzuki K, et al. . Immunoproteasome Overexpression Underlies the Pathogenesis of Thyroid Oncocytes and Primary Hypothyroidism: Studies in Humans and Mice. PloS One (2009) 4(11):e7857. 10.1371/journal.pone.0007857
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0007857</ArticleId>
            <ArticleId IdType="pmc">PMC2773418</ArticleId>
            <ArticleId IdType="pubmed">19924240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Muller-Hocker J, Aust D, Napiwotzky J, Münscher C, Link TA, Seibel P, et al. . Defects of the Respiratory Chain in Oxyphil and Chief Cells of the Normal Parathyroid and in Hyperfunction. Hum Pathol (1996) 27(6):532–41. 10.1016/S0046-8177(96)90158-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0046-8177(96)90158-6</ArticleId>
            <ArticleId IdType="pubmed">8666361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Muller-Hocker J, Schafer S, Krebs S, Blum H, Zsurka G, Kunz WS, et al. . Oxyphil Cell Metaplasia in the Parathyroids is Characterized by Somatic Mitochondrial DNA Mutations in NADH Dehydrogenase Genes and Cytochrome C Oxidase Activity-Impairing Genes. Am J Pathol (2014) 184(11):2922–35. 10.1016/j.ajpath.2014.07.015
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2014.07.015</ArticleId>
            <ArticleId IdType="pubmed">25418474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tallini G. Oncocytic Tumours. Virchows Arch (1998) 433(1):5–12. 10.1007/s004280050209
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004280050209</ArticleId>
            <ArticleId IdType="pubmed">9692819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tallini G, Carcangiu ML, Rosai J. Oncocytic Neoplasms of the Thyroid Gland. Acta Pathol Jpn (1992) 42:305–15. 10.1111/j.1440-1827.1992.tb02879.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1827.1992.tb02879.x</ArticleId>
            <ArticleId IdType="pubmed">1636432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asa SL. My Approach to Oncocytic Tumours of the Thyroid. J Clin Pathol (2004) 57(3):225–32. 10.1136/jcp.2003.008474
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jcp.2003.008474</ArticleId>
            <ArticleId IdType="pmc">PMC1770246</ArticleId>
            <ArticleId IdType="pubmed">14990587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ganly I, Ricarte FJ, Eng S, Ghossein R, Morris LGT, Liang Y, et al. . Genomic Dissection of Hurthle Cell Carcinoma Reveals a Unique Class of Thyroid Malignancy. J Clin Endocrinol Metab (2013) 98(5):E962–72. 10.1210/jc.2012-3539
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2012-3539</ArticleId>
            <ArticleId IdType="pmc">PMC5393465</ArticleId>
            <ArticleId IdType="pubmed">23543667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Grant CS, Barr D, Goellner JR, Hay ID. Benign Hürthle Cell Tumors of the Thyroid: A Diagnosis to be Trusted? World J Surg (1988) 12:488–95. 10.1007/BF01655429
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01655429</ArticleId>
            <ArticleId IdType="pubmed">3048000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Belchetz G, Cheung CC, Freeman J, Rosen IB, Witterick IJ, Asa SL. Hurthle Cell Tumors: Using Molecular Techniques to Define a Novel Classification System. Arch Otolaryngol Head Neck Surg (2002) 128(3):237–40. 10.1001/archotol.128.3.237
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archotol.128.3.237</ArticleId>
            <ArticleId IdType="pubmed">11886336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL. Molecular Basis of Hurthle Cell Papillary Thyroid Carcinoma. J Clin Endocrinol Metab (2000) 85(2):878–82. 10.1210/jc.85.2.878
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.85.2.878</ArticleId>
            <ArticleId IdType="pubmed">10690905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yamashina M. Follicular Neoplasms of the Thyroid. Total Circumferential Eval Fibrous Capsule Am J Surg Pathol (1992) 16:392–400. 10.1097/00000478-199204000-00008
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000478-199204000-00008</ArticleId>
            <ArticleId IdType="pubmed">1373582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Oh HS, Kim SJ, Song E, Lee Y-M, Sung T-Y, Kim WG, et al. . Modified Transverse-Vertical Gross Examination: A Better Method for the Detection of Definite Capsular Invasion in Encapsulated Follicular-Patterned Thyroid Neoplasms. Endocr Pathol (2019) 30(2):106–12. 10.1007/s12022-019-9565-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-019-9565-8</ArticleId>
            <ArticleId IdType="pubmed">30661168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhu Y, Li Y, Jung CK, Song DE, Hang J-F, Liu Z, et al. . Histopathologic Assessment of Capsular Invasion in Follicular Thyroid Neoplasms-an Observer Variation Study. Endocr Pathol (2020) 31(2):132–40. 10.1007/s12022-020-09620-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-020-09620-7</ArticleId>
            <ArticleId IdType="pubmed">32236857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mete O, Asa SL. Thyroid Tumor Capsular Invasion: The Bottom Line or Much Ado About Nothing? Endocr Pathol (2020) 31(2):141–2. 10.1007/s12022-020-09621-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-020-09621-6</ArticleId>
            <ArticleId IdType="pubmed">32212065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asa SL, de Jesus AC, Kerr D, Mete O, Nose V, Papotti M, et al. . Thyroid. In: Mete O, Asa SL, editors. Endocrine Pathology. Cambridge University Press. (2016) p. 398–572.</Citation>
        </Reference>
        <Reference>
          <Citation>
Asa SL. The Current Histologic Classification of Thyroid Cancer. Endocrinol Metab Clin North Am (2019) 48(1):1–22. 10.1016/j.ecl.2018.10.001
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ecl.2018.10.001</ArticleId>
            <ArticleId IdType="pubmed">30717895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
The Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell (2014) 159(3):676–90. 10.1016/j.cell.2014.09.050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2014.09.050</ArticleId>
            <ArticleId IdType="pmc">PMC4243044</ArticleId>
            <ArticleId IdType="pubmed">25417114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, et al. . RAS Point Mutations and PAX8-PPAR Gamma Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular Carcinoma. J Clin Endocrinol Metab (2003) 88(5):2318–26. 10.1210/jc.2002-021907
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2002-021907</ArticleId>
            <ArticleId IdType="pubmed">12727991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lloyd RV, Osamura RY, Kloppel G, Rosai J. Who Classification of Tumours of Endocrine Organs. 4th edition. Lyon: IARC:  (2017).</Citation>
        </Reference>
        <Reference>
          <Citation>
Asa SL. The Evolution of Differentiated Thyroid Cancer. Pathol (2017) 49(3):229–37. 10.1016/j.pathol.2017.01.001
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pathol.2017.01.001</ArticleId>
            <ArticleId IdType="pubmed">28279477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asa SL, Giordano TJ, LiVolsi VA. Implications of the TCGA Genomic Characterization of Papillary Thyroid Carcinoma for Thyroid Pathology: Does Follicular Variant Papillary Thyroid Carcinoma Exist? Thyroid (2015) 25(1):1–2. 10.1089/thy.2014.0540
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2014.0540</ArticleId>
            <ArticleId IdType="pubmed">25409450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LDR, et al. . Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol (2016) 2(8):1023–9. 10.1001/jamaoncol.2016.2205
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2016.2205</ArticleId>
            <ArticleId IdType="pmc">PMC5539411</ArticleId>
            <ArticleId IdType="pubmed">27078145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xu B, Reznik E, Tuttle RM, Knauf J, Fagin JA, Katabi N, et al. . Outcome and Molecular Characteristics of non-Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma With Oncocytic Features. Endocrine (2019) 64(1):97–108. 10.1007/s12020-019-01848-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-019-01848-6</ArticleId>
            <ArticleId IdType="pmc">PMC6657696</ArticleId>
            <ArticleId IdType="pubmed">30689169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chindris AM, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, et al. . Clinical and Molecular Features of Hurthle Cell Carcinoma of the Thyroid. J Clin Endocrinol Metab (2015) 100(1):55–62. 10.1210/jc.2014-1634
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2014-1634</ArticleId>
            <ArticleId IdType="pubmed">25259908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ganly I, Makarov V, Deraje S, Dong YY, Reznik E, Seshan V, et al. . Integrated Genomic Analysis of Hurthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell (2018) 34(2):256–70. 10.1016/j.ccell.2018.07.002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.07.002</ArticleId>
            <ArticleId IdType="pmc">PMC6247912</ArticleId>
            <ArticleId IdType="pubmed">30107176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maximo V, Sobrinho-Simoes M. Hurthle Cell Tumours of the Thyroid. A Review With Emphasis on Mitochondrial Abnormalities With Clinical Relevance. Virchows Arch (2000) 437(2):107–15. 10.1007/s004280000219
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004280000219</ArticleId>
            <ArticleId IdType="pubmed">10993269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tallini G, Hsueh A, Liu S, Garcia-Rostan G, Speicher MR, Ward DC. Frequent Chromosomal DNA Unbalance in Thyroid Oncocytic (Hurthle Cell) Neoplasms Detected by Comparative Genomic Hybridization. Lab Invest (1999) 79(5):547–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10334566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schark C, Fulton N, Jacoby RF, Westbrook CA, Straus FHII. Kaplan EL. N-Ras 61 Oncogene Mutations in Hürthle Cell Tumors. Surgery (1990) 108:994–1000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2247846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kostoglou-Athanassiou I, Pappas A, Gogou L, Kaldrymides P. Scintigraphy With [111In]Octreotide and 201Tl in a Hurthle Cell Thyroid Carcinoma Without Detectable Radio-Iodine Uptake. Rep Case Rev Literature Horm Res (2003) 60(4):205–8. 10.1159/000073234
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000073234</ArticleId>
            <ArticleId IdType="pubmed">14530610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, et al. . Prognostic Factors in Patients With Hurthle Cell Neoplasms of the Thyroid. Cancer (2003) 97(5):1186–94. 10.1002/cncr.11176
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.11176</ArticleId>
            <ArticleId IdType="pubmed">12599224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Berho M, Suster S. The Oncocytic Variant of Papillary Carcinoma of the Thyroid. A Clinicopathologic Study of 15 Cases. Hum Pathol (1997) 28:47–53. 10.1016/S0046-8177(97)90278-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0046-8177(97)90278-1</ArticleId>
            <ArticleId IdType="pubmed">9013831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hernandez-Prera JC, Machado RA, Asa SL, Baloch Z, Faquin WC, Ghossein R, et al. . Pathologic Reporting of Tall-Cell Variant of Papillary Thyroid Cancer: Have We Reached a Consensus? Thyroid (2017) 27(12):1498–504. 10.1089/thy.2017.0280
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2017.0280</ArticleId>
            <ArticleId IdType="pubmed">29020884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baloch ZW, LiVolsi VA. Warthin-Like Papillary Carcinoma of the Thyroid. Arch Pathol Lab Med (2000) 124(8):1192–5. 10.5858/2000-124-1192-WLPCOT
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5858/2000-124-1192-WLPCOT</ArticleId>
            <ArticleId IdType="pubmed">10923082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Apel RL, Asa SL, LiVolsi VA. Papillary Hürthle Cell Carcinoma With Lymphocytic Stroma. “Warthin-Like Tumor” of the Thyroid. Am J Surg Pathol (1995) 19:810–4. 10.1097/00000478-199507000-00009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000478-199507000-00009</ArticleId>
            <ArticleId IdType="pubmed">7793479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carr AA, Yen TWF, Ortiz DI, Hunt BC, Fareau G, Massey BL, et al. . Patients With Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls. Thyroid (2018) 28(11):1462–7. 10.1089/thy.2017.0603
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2017.0603</ArticleId>
            <ArticleId IdType="pubmed">30215297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Han F, Zhang L, Zhang S, Zhou H, Yi X. Occult Oncocytic Papillary Thyroid Carcinoma With Lymphoid Stroma (Warthin-Like Tumor): Report of a Case With Concomitant Mutations of BRAF V600E and V600K. Int J Clin Exp Pathol (2015) 8(5):5896–901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4503186</ArticleId>
            <ArticleId IdType="pubmed">26191315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asa SL, Mete O. Thyroid Neuroendocrine Neoplasms. In: Asa SL, La Rosa S, Mete O, editors. The Specrtum of Neuropendocrine Neoplasia. Cham, Switzerland: Springer;  (2020). p. 119–36. 10.1007/978-3-030-54391-4_7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-030-54391-4_7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
LiVolsi VA. Neuroendocrine Tumors of the Thyroid and Their Mimics. Endocr Pathol (2021). in press. 10.1007/s12022-021-09672-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-021-09672-3</ArticleId>
            <ArticleId IdType="pubmed">33687689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carcangiu ML, Zampi G, Rosai J. Poorly Differentiated (“Insular”) Thyroid Carcinoma. A Reinterpretation of Langhans’ “Wuchernde Struma”. Am J Surg Pathol (1984) 8:655–68. 10.1097/00000478-198409000-00005
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000478-198409000-00005</ArticleId>
            <ArticleId IdType="pubmed">6476195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baloch Z, Mete O, Asa SL. Immunohistochemical Biomarkers in Thyroid Pathology. Endocr Pathol (2018) 29(2):91–112. 10.1007/s12022-018-9532-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-018-9532-9</ArticleId>
            <ArticleId IdType="pubmed">29744727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Metovic J, Vignale C, Annaratone L, Osella-Abate S, Maletta F, Rapa I, et al. . The Oncocytic Variant of Poorly Differentiated Thyroid Carcinoma Shows a Specific Immune-Related Gene Expression Profile. J Clin Endocrinol Metab (2020) 105(12). 10.1210/clinem/dgaa655
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/clinem/dgaa655</ArticleId>
            <ArticleId IdType="pubmed">32936917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hodgson A, Pakbaz S, Tayyari F, Young JEM, Mete O. Diagnostic Pitfall: Parathyroid Carcinoma Expands the Spectrum of Calcitonin and Calcitonin Gene-Related Peptide Expressing Neuroendocrine Neoplasms. Endocr Pathol (2019) 30(2):168–72. 10.1007/s12022-019-9572-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-019-9572-9</ArticleId>
            <ArticleId IdType="pubmed">30903444</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34012422</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1664-2392</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in endocrinology</Title>
          <ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Oncocytic Change in Thyroid Pathology.</ArticleTitle>
        <Pagination>
          <StartPage>678119</StartPage>
          <MedlinePgn>678119</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">678119</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2021.678119</ELocationID>
        <Abstract>
          <AbstractText>Oncocytes are cells that have abundant eosinophilic cytoplasm due to the accumulation of mitochondria; they are also known as oxyphils. In the thyroid they have been called Hürthle cells but this is a misnomer, since Hürthle described C cells; for this reason, we propose the use of "oncocyte" as a scientific term rather than an incorrect eponym. Oncocytic change occurs in nontumorous thyroid disorders, in benign and malignant tumors of thyroid follicular cells, in tumors composed of thyroid C cells, and intrathyroidal parathyroid proliferations as well as in metastatic lesions. The morphology of primary oncocytic thyroid tumors is similar to that of their non-oncocytic counterparts but also is complicated by the cytologic features of these cells that include both abundant eosinophilic cytoplasm and large cherry red nucleoli. The molecular alterations in oncocytic thyroid tumors echo those of their non-oncocytic counterparts but in addition feature mitochondrial DNA mutations as well as chromosomal gains and losses. In this review we emphasize the importance of recognition of the spectrum of oncocytic thyroid pathology. The cell of origin, morphologic features including architecture, nuclear atypia and invasive growth, as well as high grade features such as mitoses and necrosis, enable accurate classification of these lesions. The molecular alterations underlying the pathological entity are associated with genetic alterations associated with oncocytic change. The arbitrary cut-off of 75% oncocytic change to classify a lesion as an oncocytic variant brings another complexity to the classification scheme of tumors that frequently have mixed oncocytic and non-oncocytic components. This controversial and often confusing area of thyroid pathology requires thoughtful and cautious investigation to clarify accurate diagnosis, prognosis and prediction for patients with oncocytic thyroid lesions.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Asa and Mete.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Asa</LastName>
            <ForeName>Sylvia L</ForeName>
            <Initials>SL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University Hospitals Cleveland Medical Center, Cleveland, OH, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Case Western Reserve University, Cleveland, OH, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University Health Network, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mete</LastName>
            <ForeName>Ozgur</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, University Health Network, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>05</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Endocrinol (Lausanne)</MedlineTA>
        <NlmUniqueID>101555782</NlmUniqueID>
        <ISSNLinking>1664-2392</ISSNLinking>
      </MedlineJournalInfo>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C536913">Thyroid cancer, Hurthle cell</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018249" MajorTopicYN="N">Adenoma, Oxyphilic</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024862" MajorTopicYN="N">Oxyphil Cells</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013961" MajorTopicYN="N">Thyroid Gland</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013964" MajorTopicYN="N">Thyroid Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Hürthle cell</Keyword>
        <Keyword MajorTopicYN="Y">immunohistochemistry</Keyword>
        <Keyword MajorTopicYN="Y">molecular</Keyword>
        <Keyword MajorTopicYN="Y">neoplasia</Keyword>
        <Keyword MajorTopicYN="Y">oncocytes</Keyword>
        <Keyword MajorTopicYN="Y">thyroid</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>40</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34012422</ArticleId>
        <ArticleId IdType="pmc">PMC8127945</ArticleId>
        <ArticleId IdType="doi">10.3389/fendo.2021.678119</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Asa SL. Survival Guide to Endocrine Pathology. Virginia: Innovative Pathology Press;  (2020).</Citation>
        </Reference>
        <Reference>
          <Citation>
Asa SL, Mete O. Parathyroids. In: Mills SE, editor. Histology for Pathologists. Philadelphia: Wolters Kluwer;  (2018). p. 1201–24.</Citation>
        </Reference>
        <Reference>
          <Citation>
Kovacs K, Horvath E, Bilbao JM. Oncocytes in the Anterior Lobe of the Human Pituitary Gland. A Light and Electron Microscopic Study. Acta Neuropathol (Berl) (1974) 27:43–54. 10.1007/BF00687239
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00687239</ArticleId>
            <ArticleId IdType="pubmed">4363741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asa SL, Kovacs K, Bilbao JM. The Pars Tuberalis of the Human Pituitary. A Histologic, Immunohistochemical, Ultrastructural and Immunoelectron Microscopic Analysis. Virchows Arch [A] (1983) 399:49–59. 10.1007/BF00666218
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00666218</ArticleId>
            <ArticleId IdType="pubmed">6299000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nesland JM, Sobrinho-Simoes M, Holm R, Sambade MC, Johannessen JV. Hürthle Cell Lesions of the Thyroid: A Combined Study Using Transmission Electron Microscopy, Scanning Electron Microscopy and Immunocytochemistry. Ultrastructrual Pathol (1985) 8:131–42. 10.3109/01913128509141518
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/01913128509141518</ArticleId>
            <ArticleId IdType="pubmed">4082297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sobrinho-Simoes M, Nesland JM, Holm R, Sambade MC, Johannessen JV. Hürthle Cell and Mitochondrion-Rich Papillary Carcinomas of the Thyroid Gland: An Ultrastructural and Immunocytochemical Study. Ultrastruct Pathol (1985) 8:131–42. 10.3109/01913128509142147
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/01913128509142147</ArticleId>
            <ArticleId IdType="pubmed">4060255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cameselle-Teijeiro J, Ferreira R, Carames N, Abdulkader I, Máximo V, Soares P, et al. . Absence of the BRAF and the GRIM-19 Mutations in Oncocytic (Hurthle Cell) Solid Cell Nests of the Thyroid. Am J Clin Pathol (2012) 137(4):612–8. 10.1309/AJCPB0RXYPACLL5K
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1309/AJCPB0RXYPACLL5K</ArticleId>
            <ArticleId IdType="pubmed">22431538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hurthle K. Beitrage Zur Kenntiss Der Secretionsvorgangs in Der Schilddruse. Arch Gesamte Physiol (1894) 56:1–44. 10.1007/BF01662011
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01662011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Askanazy M. Patologisch Anatomische Beitrage Zur Kenntiss Des Morbus Basedowii, Insbesondere Uber Die Dabei Auftretende Muskelerkrankung. Deutsch Arch Klin Med (1898) 61:118–86.</Citation>
        </Reference>
        <Reference>
          <Citation>
Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M. Mitochondrial DNA Somatic Mutations (Point Mutations and Large Deletions) and Mitochondrial DNA Variants in Human Thyroid Pathology: A Study With Emphasis on Hurthle Cell Tumors. Am J Pathol (2002) 160(5):1857–65. 10.1016/S0002-9440(10)61132-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)61132-7</ArticleId>
            <ArticleId IdType="pmc">PMC1850872</ArticleId>
            <ArticleId IdType="pubmed">12000737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maximo V, Botelho T, Capela J, Soares P, Lima J, Taveira A, et al. . Somatic and Germline Mutation in GRIM-19, a Dual Function Gene Involved in Mitochondrial Metabolism and Cell Death, is Linked to Mitochondrion-Rich (Hurthle Cell) Tumours of the Thyroid. Br J Cancer (2005) 92(10):1892–8. 10.1038/sj.bjc.6602547
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6602547</ArticleId>
            <ArticleId IdType="pmc">PMC2361763</ArticleId>
            <ArticleId IdType="pubmed">15841082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mete O, Asa SL. Oncocytes, Oxyphils, Hurthle, and Askanazy Cells: Morphological and Molecular Features of Oncocytic Thyroid Nodules. Endocr Pathol (2010) 21(1):16–24. 10.1007/s12022-009-9102-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-009-9102-2</ArticleId>
            <ArticleId IdType="pubmed">20013317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kimura HJ, Chen CY, Tzou SC, Rocchi R, Landek-Salgado MA, Suzuki K, et al. . Immunoproteasome Overexpression Underlies the Pathogenesis of Thyroid Oncocytes and Primary Hypothyroidism: Studies in Humans and Mice. PloS One (2009) 4(11):e7857. 10.1371/journal.pone.0007857
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0007857</ArticleId>
            <ArticleId IdType="pmc">PMC2773418</ArticleId>
            <ArticleId IdType="pubmed">19924240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Muller-Hocker J, Aust D, Napiwotzky J, Münscher C, Link TA, Seibel P, et al. . Defects of the Respiratory Chain in Oxyphil and Chief Cells of the Normal Parathyroid and in Hyperfunction. Hum Pathol (1996) 27(6):532–41. 10.1016/S0046-8177(96)90158-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0046-8177(96)90158-6</ArticleId>
            <ArticleId IdType="pubmed">8666361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Muller-Hocker J, Schafer S, Krebs S, Blum H, Zsurka G, Kunz WS, et al. . Oxyphil Cell Metaplasia in the Parathyroids is Characterized by Somatic Mitochondrial DNA Mutations in NADH Dehydrogenase Genes and Cytochrome C Oxidase Activity-Impairing Genes. Am J Pathol (2014) 184(11):2922–35. 10.1016/j.ajpath.2014.07.015
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2014.07.015</ArticleId>
            <ArticleId IdType="pubmed">25418474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tallini G. Oncocytic Tumours. Virchows Arch (1998) 433(1):5–12. 10.1007/s004280050209
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004280050209</ArticleId>
            <ArticleId IdType="pubmed">9692819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tallini G, Carcangiu ML, Rosai J. Oncocytic Neoplasms of the Thyroid Gland. Acta Pathol Jpn (1992) 42:305–15. 10.1111/j.1440-1827.1992.tb02879.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1440-1827.1992.tb02879.x</ArticleId>
            <ArticleId IdType="pubmed">1636432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asa SL. My Approach to Oncocytic Tumours of the Thyroid. J Clin Pathol (2004) 57(3):225–32. 10.1136/jcp.2003.008474
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jcp.2003.008474</ArticleId>
            <ArticleId IdType="pmc">PMC1770246</ArticleId>
            <ArticleId IdType="pubmed">14990587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ganly I, Ricarte FJ, Eng S, Ghossein R, Morris LGT, Liang Y, et al. . Genomic Dissection of Hurthle Cell Carcinoma Reveals a Unique Class of Thyroid Malignancy. J Clin Endocrinol Metab (2013) 98(5):E962–72. 10.1210/jc.2012-3539
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2012-3539</ArticleId>
            <ArticleId IdType="pmc">PMC5393465</ArticleId>
            <ArticleId IdType="pubmed">23543667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Grant CS, Barr D, Goellner JR, Hay ID. Benign Hürthle Cell Tumors of the Thyroid: A Diagnosis to be Trusted? World J Surg (1988) 12:488–95. 10.1007/BF01655429
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01655429</ArticleId>
            <ArticleId IdType="pubmed">3048000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Belchetz G, Cheung CC, Freeman J, Rosen IB, Witterick IJ, Asa SL. Hurthle Cell Tumors: Using Molecular Techniques to Define a Novel Classification System. Arch Otolaryngol Head Neck Surg (2002) 128(3):237–40. 10.1001/archotol.128.3.237
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archotol.128.3.237</ArticleId>
            <ArticleId IdType="pubmed">11886336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL. Molecular Basis of Hurthle Cell Papillary Thyroid Carcinoma. J Clin Endocrinol Metab (2000) 85(2):878–82. 10.1210/jc.85.2.878
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.85.2.878</ArticleId>
            <ArticleId IdType="pubmed">10690905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yamashina M. Follicular Neoplasms of the Thyroid. Total Circumferential Eval Fibrous Capsule Am J Surg Pathol (1992) 16:392–400. 10.1097/00000478-199204000-00008
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000478-199204000-00008</ArticleId>
            <ArticleId IdType="pubmed">1373582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Oh HS, Kim SJ, Song E, Lee Y-M, Sung T-Y, Kim WG, et al. . Modified Transverse-Vertical Gross Examination: A Better Method for the Detection of Definite Capsular Invasion in Encapsulated Follicular-Patterned Thyroid Neoplasms. Endocr Pathol (2019) 30(2):106–12. 10.1007/s12022-019-9565-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-019-9565-8</ArticleId>
            <ArticleId IdType="pubmed">30661168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhu Y, Li Y, Jung CK, Song DE, Hang J-F, Liu Z, et al. . Histopathologic Assessment of Capsular Invasion in Follicular Thyroid Neoplasms-an Observer Variation Study. Endocr Pathol (2020) 31(2):132–40. 10.1007/s12022-020-09620-7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-020-09620-7</ArticleId>
            <ArticleId IdType="pubmed">32236857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mete O, Asa SL. Thyroid Tumor Capsular Invasion: The Bottom Line or Much Ado About Nothing? Endocr Pathol (2020) 31(2):141–2. 10.1007/s12022-020-09621-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-020-09621-6</ArticleId>
            <ArticleId IdType="pubmed">32212065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asa SL, de Jesus AC, Kerr D, Mete O, Nose V, Papotti M, et al. . Thyroid. In: Mete O, Asa SL, editors. Endocrine Pathology. Cambridge University Press. (2016) p. 398–572.</Citation>
        </Reference>
        <Reference>
          <Citation>
Asa SL. The Current Histologic Classification of Thyroid Cancer. Endocrinol Metab Clin North Am (2019) 48(1):1–22. 10.1016/j.ecl.2018.10.001
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ecl.2018.10.001</ArticleId>
            <ArticleId IdType="pubmed">30717895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
The Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell (2014) 159(3):676–90. 10.1016/j.cell.2014.09.050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2014.09.050</ArticleId>
            <ArticleId IdType="pmc">PMC4243044</ArticleId>
            <ArticleId IdType="pubmed">25417114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, et al. . RAS Point Mutations and PAX8-PPAR Gamma Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular Carcinoma. J Clin Endocrinol Metab (2003) 88(5):2318–26. 10.1210/jc.2002-021907
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2002-021907</ArticleId>
            <ArticleId IdType="pubmed">12727991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lloyd RV, Osamura RY, Kloppel G, Rosai J. Who Classification of Tumours of Endocrine Organs. 4th edition. Lyon: IARC:  (2017).</Citation>
        </Reference>
        <Reference>
          <Citation>
Asa SL. The Evolution of Differentiated Thyroid Cancer. Pathol (2017) 49(3):229–37. 10.1016/j.pathol.2017.01.001
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pathol.2017.01.001</ArticleId>
            <ArticleId IdType="pubmed">28279477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asa SL, Giordano TJ, LiVolsi VA. Implications of the TCGA Genomic Characterization of Papillary Thyroid Carcinoma for Thyroid Pathology: Does Follicular Variant Papillary Thyroid Carcinoma Exist? Thyroid (2015) 25(1):1–2. 10.1089/thy.2014.0540
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2014.0540</ArticleId>
            <ArticleId IdType="pubmed">25409450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LDR, et al. . Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol (2016) 2(8):1023–9. 10.1001/jamaoncol.2016.2205
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2016.2205</ArticleId>
            <ArticleId IdType="pmc">PMC5539411</ArticleId>
            <ArticleId IdType="pubmed">27078145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Xu B, Reznik E, Tuttle RM, Knauf J, Fagin JA, Katabi N, et al. . Outcome and Molecular Characteristics of non-Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma With Oncocytic Features. Endocrine (2019) 64(1):97–108. 10.1007/s12020-019-01848-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-019-01848-6</ArticleId>
            <ArticleId IdType="pmc">PMC6657696</ArticleId>
            <ArticleId IdType="pubmed">30689169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chindris AM, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, et al. . Clinical and Molecular Features of Hurthle Cell Carcinoma of the Thyroid. J Clin Endocrinol Metab (2015) 100(1):55–62. 10.1210/jc.2014-1634
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2014-1634</ArticleId>
            <ArticleId IdType="pubmed">25259908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ganly I, Makarov V, Deraje S, Dong YY, Reznik E, Seshan V, et al. . Integrated Genomic Analysis of Hurthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell (2018) 34(2):256–70. 10.1016/j.ccell.2018.07.002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.07.002</ArticleId>
            <ArticleId IdType="pmc">PMC6247912</ArticleId>
            <ArticleId IdType="pubmed">30107176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maximo V, Sobrinho-Simoes M. Hurthle Cell Tumours of the Thyroid. A Review With Emphasis on Mitochondrial Abnormalities With Clinical Relevance. Virchows Arch (2000) 437(2):107–15. 10.1007/s004280000219
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004280000219</ArticleId>
            <ArticleId IdType="pubmed">10993269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tallini G, Hsueh A, Liu S, Garcia-Rostan G, Speicher MR, Ward DC. Frequent Chromosomal DNA Unbalance in Thyroid Oncocytic (Hurthle Cell) Neoplasms Detected by Comparative Genomic Hybridization. Lab Invest (1999) 79(5):547–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10334566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schark C, Fulton N, Jacoby RF, Westbrook CA, Straus FHII. Kaplan EL. N-Ras 61 Oncogene Mutations in Hürthle Cell Tumors. Surgery (1990) 108:994–1000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2247846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kostoglou-Athanassiou I, Pappas A, Gogou L, Kaldrymides P. Scintigraphy With [111In]Octreotide and 201Tl in a Hurthle Cell Thyroid Carcinoma Without Detectable Radio-Iodine Uptake. Rep Case Rev Literature Horm Res (2003) 60(4):205–8. 10.1159/000073234
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000073234</ArticleId>
            <ArticleId IdType="pubmed">14530610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, et al. . Prognostic Factors in Patients With Hurthle Cell Neoplasms of the Thyroid. Cancer (2003) 97(5):1186–94. 10.1002/cncr.11176
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.11176</ArticleId>
            <ArticleId IdType="pubmed">12599224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Berho M, Suster S. The Oncocytic Variant of Papillary Carcinoma of the Thyroid. A Clinicopathologic Study of 15 Cases. Hum Pathol (1997) 28:47–53. 10.1016/S0046-8177(97)90278-1
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0046-8177(97)90278-1</ArticleId>
            <ArticleId IdType="pubmed">9013831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hernandez-Prera JC, Machado RA, Asa SL, Baloch Z, Faquin WC, Ghossein R, et al. . Pathologic Reporting of Tall-Cell Variant of Papillary Thyroid Cancer: Have We Reached a Consensus? Thyroid (2017) 27(12):1498–504. 10.1089/thy.2017.0280
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2017.0280</ArticleId>
            <ArticleId IdType="pubmed">29020884</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baloch ZW, LiVolsi VA. Warthin-Like Papillary Carcinoma of the Thyroid. Arch Pathol Lab Med (2000) 124(8):1192–5. 10.5858/2000-124-1192-WLPCOT
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5858/2000-124-1192-WLPCOT</ArticleId>
            <ArticleId IdType="pubmed">10923082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Apel RL, Asa SL, LiVolsi VA. Papillary Hürthle Cell Carcinoma With Lymphocytic Stroma. “Warthin-Like Tumor” of the Thyroid. Am J Surg Pathol (1995) 19:810–4. 10.1097/00000478-199507000-00009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000478-199507000-00009</ArticleId>
            <ArticleId IdType="pubmed">7793479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carr AA, Yen TWF, Ortiz DI, Hunt BC, Fareau G, Massey BL, et al. . Patients With Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls. Thyroid (2018) 28(11):1462–7. 10.1089/thy.2017.0603
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2017.0603</ArticleId>
            <ArticleId IdType="pubmed">30215297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Han F, Zhang L, Zhang S, Zhou H, Yi X. Occult Oncocytic Papillary Thyroid Carcinoma With Lymphoid Stroma (Warthin-Like Tumor): Report of a Case With Concomitant Mutations of BRAF V600E and V600K. Int J Clin Exp Pathol (2015) 8(5):5896–901.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4503186</ArticleId>
            <ArticleId IdType="pubmed">26191315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asa SL, Mete O. Thyroid Neuroendocrine Neoplasms. In: Asa SL, La Rosa S, Mete O, editors. The Specrtum of Neuropendocrine Neoplasia. Cham, Switzerland: Springer;  (2020). p. 119–36. 10.1007/978-3-030-54391-4_7
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-030-54391-4_7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
LiVolsi VA. Neuroendocrine Tumors of the Thyroid and Their Mimics. Endocr Pathol (2021). in press. 10.1007/s12022-021-09672-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-021-09672-3</ArticleId>
            <ArticleId IdType="pubmed">33687689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carcangiu ML, Zampi G, Rosai J. Poorly Differentiated (“Insular”) Thyroid Carcinoma. A Reinterpretation of Langhans’ “Wuchernde Struma”. Am J Surg Pathol (1984) 8:655–68. 10.1097/00000478-198409000-00005
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000478-198409000-00005</ArticleId>
            <ArticleId IdType="pubmed">6476195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baloch Z, Mete O, Asa SL. Immunohistochemical Biomarkers in Thyroid Pathology. Endocr Pathol (2018) 29(2):91–112. 10.1007/s12022-018-9532-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-018-9532-9</ArticleId>
            <ArticleId IdType="pubmed">29744727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Metovic J, Vignale C, Annaratone L, Osella-Abate S, Maletta F, Rapa I, et al. . The Oncocytic Variant of Poorly Differentiated Thyroid Carcinoma Shows a Specific Immune-Related Gene Expression Profile. J Clin Endocrinol Metab (2020) 105(12). 10.1210/clinem/dgaa655
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/clinem/dgaa655</ArticleId>
            <ArticleId IdType="pubmed">32936917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hodgson A, Pakbaz S, Tayyari F, Young JEM, Mete O. Diagnostic Pitfall: Parathyroid Carcinoma Expands the Spectrum of Calcitonin and Calcitonin Gene-Related Peptide Expressing Neuroendocrine Neoplasms. Endocr Pathol (2019) 30(2):168–72. 10.1007/s12022-019-9572-9
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-019-9572-9</ArticleId>
            <ArticleId IdType="pubmed">30903444</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
